Collaborations - Additional Information (Details)					3 Months Ended
	Jul. 07, 2020 USD ($)	May 09, 2019 USD ($) $ / shares shares	Nov. 01, 2018	Oct. 31, 2017 shares	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration termination date					Apr. 27, 2022
Research and development					$ 35,944,000	$ 25,962,000
Revenue recognized					9,622,000	18,702,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000,000.0
Collaboration agreement transaction price	150,000,000.0
Revenue recognized recorded in deferred revenue					6,600,000
Unsatisfied performance obligation					76,400,000		$ 81,800,000
Cost reimbursement payment received					100,000
Milestone receivable					0
Royalty receivable					0
Unbilled accounts receivable					1,300,000
Research and development					$ 0
Remaining research term of collaboration					2 years
Revenue recognized					$ 11,600,000	11,600,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000,000.0
Revenue recognized recorded in deferred revenue					4,200,000
Revenue recognized					9,500,000	9,500,000
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000,000.0
Revenue recognized recorded in deferred revenue					2,400,000
Revenue recognized					2,100,000	2,100,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000,000
Commercial Milestone Payments	700,000,000.0
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000,000.0
Commercial Milestone Payments	$ 400,000,000.0
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue					3,000,000.0
Unsatisfied performance obligation					16,200,000		$ 19,200,000
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized					$ 3,000,000.0	$ 7,100,000
Vertex Agreement | Series B-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900,000
Non refundable upfront payment received		$ 50,000,000.0
Issuance of shares, Shares | shares		3,059,695
Stock issued price per share | $ / shares		$ 6.54
Preferred stock premium		$ 5,900,000
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000,000.0
Revenue remaining research term					9 months 18 days
Compound Collaboration | Series A Preferred Units
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares | shares				886,305
Stock split, conversion ratio			100
Share-based compensation vesting period			3 years